We sought to investigate the underlying mechanism of action of the long noncoding RNA （IncRNA） LOC283070 in the development of androgen independence in prostate cancer. The interactions between LOC283070 and target ...We sought to investigate the underlying mechanism of action of the long noncoding RNA （IncRNA） LOC283070 in the development of androgen independence in prostate cancer. The interactions between LOC283070 and target proteins were investigated by RNA pull-down and RNA-binding protein immunoprecipitation （RIP） assays. Subceilular fractionation and quantitative reverse transcription-polymerase chain reaction （qRT-PCR） were used to detect the subcellular localization of LOC283070. Western blotting was performed to detect the expression of prohibitin 2 （PHB2）. Luciferase activity assays were performed to evaluate the effects of LOC283070 and PHB2 on the androgen receptor （AR） signaling pathway. A methyl thiazolyl tetrazolium （MTT） assay and a growth curve assay were used to test cell viability. Flow cytometry was performed to analyze cell cycles. A transwell assay was employed to test cell migration. We identified PHB2 as an interaction partner of LOC283070 in the pull-down and RIP experiments. Furthermore, we confirmed that the enrichment of L0C283070 with PHB2 in androgen-independent LNCaP （LNCaP-AI） cells was much greater than that in LNCaP cells. Moreover, the expression of PHB2 was not significantly different between the two cell lines, and the expression of LOC283070 in the nuclei of the LNCaP-AI cells was significantly greater than that in the LNCaP cells. In vitro data revealed that PHB2 overexpression significantly inhibited AR activity and cell proliferation and migration and induced accumulation of prostate cancer cells in GO/G1 phase. Moreover, the overexpression of LOC283070 fully abrogated the effects of PHB2 overexpression. In conclusion, we found that LOC283070 can bind to PHB2 located in the nucleus and inhibit its effect, and this is one of the mechanisms by which LOC283070 is involved in the transition of LNCaP cells into androgen-independent cells.展开更多
基金This work was supported by grants from the National Natural Science Foundation of China （No. 81702538, 81372764, and 81528015） and the Natural Science Foundation of Shandong Province （No. ZR201702160271, ZR2018MH030, and ZR2018MH025）.
文摘We sought to investigate the underlying mechanism of action of the long noncoding RNA （IncRNA） LOC283070 in the development of androgen independence in prostate cancer. The interactions between LOC283070 and target proteins were investigated by RNA pull-down and RNA-binding protein immunoprecipitation （RIP） assays. Subceilular fractionation and quantitative reverse transcription-polymerase chain reaction （qRT-PCR） were used to detect the subcellular localization of LOC283070. Western blotting was performed to detect the expression of prohibitin 2 （PHB2）. Luciferase activity assays were performed to evaluate the effects of LOC283070 and PHB2 on the androgen receptor （AR） signaling pathway. A methyl thiazolyl tetrazolium （MTT） assay and a growth curve assay were used to test cell viability. Flow cytometry was performed to analyze cell cycles. A transwell assay was employed to test cell migration. We identified PHB2 as an interaction partner of LOC283070 in the pull-down and RIP experiments. Furthermore, we confirmed that the enrichment of L0C283070 with PHB2 in androgen-independent LNCaP （LNCaP-AI） cells was much greater than that in LNCaP cells. Moreover, the expression of PHB2 was not significantly different between the two cell lines, and the expression of LOC283070 in the nuclei of the LNCaP-AI cells was significantly greater than that in the LNCaP cells. In vitro data revealed that PHB2 overexpression significantly inhibited AR activity and cell proliferation and migration and induced accumulation of prostate cancer cells in GO/G1 phase. Moreover, the overexpression of LOC283070 fully abrogated the effects of PHB2 overexpression. In conclusion, we found that LOC283070 can bind to PHB2 located in the nucleus and inhibit its effect, and this is one of the mechanisms by which LOC283070 is involved in the transition of LNCaP cells into androgen-independent cells.
